Literature DB >> 2206572

The natural course of emesis after carboplatin treatment.

M Martin1, E Diaz-Rubio, A Sánchez, J Almenarez, J M López-Vega.   

Abstract

Twenty-eight patients receiving their first cycle of carboplatin treatment (300-400 mg/m2) entered a prospective study in which the natural course and intensity of postchemotherapy emesis was evaluated. Twenty-five patients (89%) experienced nausea at some time after carboplatin treatment and twenty-three patients (82%) vomited. The median number of emetic episodes was 13.5. In the 23 patients who experienced vomiting, the mean period of latency of vomiting (time from start of carboplatin administration to onset of vomiting) was 6.25 h. The period of maximum incidence of vomiting was between 8 and 12 h (71% of patients with vomiting). Between 6 and 14 h after the start of carboplatin treatment, more than 50% of patients were continuously vomiting. Vomiting declined significantly after 24 h. According to these data, carboplatin is a severely emetic drug. Prospective antiemetic trials are necessary in order to obtain antiemetic schedules which are able to increase the tolerance to carboplatin treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206572     DOI: 10.3109/02841869009090058

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

Review 1.  Myths and realities of antiemetic treatment.

Authors:  M Martin
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.

Authors:  M Markman; A Kennedy; K Webster; G Peterson; B Kulp; J Belinson
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.

Authors:  Hirotoshi Iihara; Mototsugu Shimokawa; Toshinobu Hayashi; Hitoshi Kawazoe; Toshiaki Saeki; Keisuke Aiba; Kazuo Tamura
Journal:  Oncologist       Date:  2019-10-21

4.  Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.

Authors:  Paul J Hesketh; Oliver Wright; Gerardo Rosati; Mark Russo; Jeremey Levin; Stephen Lane; Vladimir Moiseyenko; Pierre Dube; Mikhail Kopp; Anatoly Makhson
Journal:  Support Care Cancer       Date:  2011-08-07       Impact factor: 3.603

5.  Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.

Authors:  Paul J Hesketh; Pedro Sanz-Altamira; Julie Bushey; Ann M Hesketh
Journal:  Support Care Cancer       Date:  2011-05-09       Impact factor: 3.603

6.  Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.

Authors:  Paul J Hesketh; Snezana M Bosnjak; Vlada Nikolic; Bernardo Rapoport
Journal:  Support Care Cancer       Date:  2011-12       Impact factor: 3.603

Review 7.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 8.  Drug treatment of chemotherapy-induced delayed emesis.

Authors:  R Tavorath; P J Hesketh
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 9.  Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).

Authors:  Noha Rashad; Omar Abdel-Rahman
Journal:  Drug Des Devel Ther       Date:  2017-03-24       Impact factor: 4.162

Review 10.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.